SGLT
-
Dapagliflozin (BMS512148)
Catalog No. A10285 SGLT2 inhibitorDapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Learn More -
Canagliflozin
Catalog No. A11100 SGLT2 InhibitorCanagliflozin is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2). Learn More -
EGT1442
Catalog No. A10155 -
Empagliflozin
Catalog No. A12440 Empagliflozin is a potent, selective sodium glucose co-transporter-2 inhibitor that is in development for the treatment of type 2 diabetes. Learn More -
LX-4211
Catalog No. A12680 -
Tofogliflozin
Catalog No. A12690 SGLT2 inhibitorTofogliflozin is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Learn More -
Remogliflozin
Catalog No. A13971 SGLT2 inhibitorRemogliflozin inhibits the sodium-glucose transport (SGLT2) proteins, which are responsible for glucose reabsorption in the kidney. Learn More -
Ipragliflozin
Catalog No. A13556 SGLT2 inhibitorIpragliflozin is a highly potent and selective SGLT2 inhibitor with IC50 of 2.8 nM; little and NO potency for SGLT1/3/4/5/6. Learn More -
Luseogliflozin
Catalog No. A13476 SGLT2 InhibitorLuseogliflozin is an orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor developed by Taisho Pharmaceutical for the treatment of patients with type 2 diabetes mellitus (T2DM). Learn More -
T-1095
Catalog No. A15463 Na+-glucose transporter inhibitorT-1095 is a potent and selective inhibitor of Na+-glucose cotransporters (SGLTs). Learn More -
Canagliflozin hemihydrate
Catalog No. A16817 SGLT2 inhibitorCanagliflozin hemihydrate is the hemihydrate form of canagliflozin, which is a SGLT2 inhibitor with IC50 of 2.2 nM for hSGLT2 in a cell-free assay, exhibits 413-fold selectivity over hSGLT1. Learn More -
Ertugliflozin L-pyroglutamic acid
Catalog No. A18054 SGLT inhibitorErtugliflozin pidolate belongs to the class of potent and selective inhibitors of the sodium-dependent glucose cotransporters (SGLT), more specifically the type 2 which is responsible for about 90% of the glucose reabsorption from glomerulus. Learn More -
SGL5213
Catalog No. A18723 SGLT1 inhibitorSGL5213 is a potent, oral active and low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor, with IC50 values of 29 nM and 20 nM for hSGLT1 and hSGLT2, respectively. Learn More -
Dapagliflozin impurity
Catalog No. A19103 SGLT2 inhibitorDapagliflozin impurity is an enantiomer of Dapagliflozin which is a sodium-glucose transporter 2 inhibitor. Learn More -
Licogliflozin
Catalog No. A12828 SGLT1/SGLT2 inhibitorLicogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor. Learn More